# The Bioequivalence Study of Lamotrigine Dispersible/Chewable Tablets 100mg Compared With Compressed Tablet 100 mg

> **NCT02064465** · PHASE1 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 138 (actual)

## Conditions studied

- Epilepsy

## Interventions

- **DRUG:** Lamotrigine Dispersible/Chewable tablet
- **DRUG:** Lamotrigine Compressed tablet

## Key facts

- **NCT ID:** NCT02064465
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-03-15
- **Primary completion:** 2014-07-08
- **Final completion:** 2014-07-08
- **Target enrollment:** 138 (ACTUAL)
- **Last updated:** 2017-05-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02064465

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02064465, "The Bioequivalence Study of Lamotrigine Dispersible/Chewable Tablets 100mg Compared With Compressed Tablet 100 mg". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02064465. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*